Table 2.
Baseline levels of coagulation markers
| Coagulation marker | Group A | Group B | P value | Normal range (reference value) |
| Prothrombin fragment F1+2 (nmol/l) | 2.5 (0.9–3.8) | 4.1 (2.3–6.6) | 0.20 | 0.3–1.6 |
| Soluble tissue factor (pg/ml) | 126 (73–216) | 207 (30–322) | 0.59 | 55–256 |
| Activated factor VII (mU/ml) | 61 (14–141) | 97 (20–267) | 0.52 | 16–142 |
| Tissue factor pathway inhibitor (ng/ml) | 167 (104–192) | 127 (56–200) | 0.83 | 39–149 |
| Antithrombin (%) | 78 (46–100) | 45 (16–81) | 0.09 | 80–140 |
| Protein C (%) | 63 (29–164) | 41 (16–89) | 0.34 | 65–110 |
| Plasmin–antiplasmin complexes (ng/ml) | 682 (635–788) | 727 (281–1287) | 1.0 | 221–512 |
| Tissue-type plasminogen activator (ng/ml) | 14.3 (7.0–44.6) | 11.7 (8.6–51.7) | 0.75 | 1.5–15 |
| Plasminogen activator inhibitor type 1 (ng/ml) | 135 (16–275) | 526 (129–2191) | 0.06 | 10–70 |
| Kallikrein–C1-inhibitor complex (mU/ml) | 8.2 (5.1–9.9) | 11.1 (8.5–18.5) | 0.02 | <0.6 |
| Activated factor XII–C1-inhibitor complex (mU/ml) | 1.6 (1.3–1.8) | 2.4 (1.8–4.4) | 0.02 | <0.5 |
| Platelet count (× 109/l) | 136 (90–329) | 63 (30–101) | 0.02 | 150–350 |
| Prothrombin time (s) | 13.5 (12.7–16.9) | 17.5 (15.2–26.1) | 0.05 | 10–13 |
| Activated partial thromboplastin time (s) | 25 (21–29) | 37 (27–57) | 0.02 | 21–27 |
Group A, patients with increased thrombin generation; group B, patients without increased thrombin generation. Data presented as median (range).